Ether lipid biosynthesis promotes lifespan extension and enables diverse pro-longevity paradigms in Caenorhabditis elegans
Curation statements for this article:-
Curated by eLife
eLife assessment
Using C. elegans as a model organism, the study hones in on the role of ether lipid biosynthesis as an effector of metformin--a process previously implicated in extending lifespan in response to diet--, TOR signalling, and mitochondrial interventions. The data in this paper are compelling, and a better understanding of biguanide impact on metabolism is highly important in the field.
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (eLife)
Abstract
Biguanides, including the world’s most prescribed drug for type 2 diabetes, metformin, not only lower blood sugar, but also promote longevity in preclinical models. Epidemiologic studies in humans parallel these findings, indicating favorable effects of metformin on longevity and on reducing the incidence and morbidity associated with aging-related diseases. Despite this promise, the full spectrum of molecular effectors responsible for these health benefits remains elusive. Through unbiased screening in Caenorhabditis elegans , we uncovered a role for genes necessary for ether lipid biosynthesis in the favorable effects of biguanides. We demonstrate that biguanides prompt lifespan extension by stimulating ether lipid biogenesis. Loss of the ether lipid biosynthetic machinery also mitigates lifespan extension attributable to dietary restriction, target of rapamycin (TOR) inhibition, and mitochondrial electron transport chain inhibition. A possible mechanistic explanation for this finding is that ether lipids are required for activation of longevity-promoting, metabolic stress defenses downstream of the conserved transcription factor skn-1 /Nrf. In alignment with these findings, overexpression of a single, key, ether lipid biosynthetic enzyme, fard-1 /FAR1, is sufficient to promote lifespan extension. These findings illuminate the ether lipid biosynthetic machinery as a novel therapeutic target to promote healthy aging.
Article activity feed
-
-
Author Response
Reviewer #1 (Public Review):
Cedillo et al. address the critically important question of how biguanides exert their positive effects on longevity using the powerful C. elegans model. Biguanides metformin and phenformin have been widely prescribed in the clinic to address metabolic challenges of diabetes; more recently the value of metformin in addressing specific cancers has emerged, and testing for impact on healthy human aging is getting underway. The need to understand the mechanism of biguanide action and the metabolic consequences of biguanide administration is clear.
The authors report that three genes that suppress longevity associated with metformin or phenformin treatment affect a common pathway for ether lipid biosynthesis; this ether lipid biosynthesis pathway is required for mitochondrial lifespan …
Author Response
Reviewer #1 (Public Review):
Cedillo et al. address the critically important question of how biguanides exert their positive effects on longevity using the powerful C. elegans model. Biguanides metformin and phenformin have been widely prescribed in the clinic to address metabolic challenges of diabetes; more recently the value of metformin in addressing specific cancers has emerged, and testing for impact on healthy human aging is getting underway. The need to understand the mechanism of biguanide action and the metabolic consequences of biguanide administration is clear.
The authors report that three genes that suppress longevity associated with metformin or phenformin treatment affect a common pathway for ether lipid biosynthesis; this ether lipid biosynthesis pathway is required for mitochondrial lifespan extension, eat-2 mediated dietary restriction longevity, and TOR inhibition-associated longevity, but not insulin pathway mediated longevity. Authors document with lipid profiling how ether lipids and some other lipids are impacted by phenformin vs. genetic disruption of ether lipid biosynthesis, define the tissue primarily responsible for the ether lipid biosynthesis, show that over-expression of enzyme fard-1 is sufficient to confer most of the phenformin effect, and implicate conserved stress transcription factor SKN-1 as a downstream outcome of the ether lipid change.
Strengths include the exploitation of the nematode model to address requirements not readily discerned in other models, the rigor of genetic documentation, the inclusion of metabolic profiling, the testing of multiple potential pathways that have been in the general discourse regarding metformin action, and the elaboration of a reasonably supported model that ether lipid biosynthesis is required for phenformin to activate longevity-promoting metabolic defenses downstream of conserved stress-responsive transcription factor SKN-1/NRF2. The novelty includes that ether lipids are directly linked to lifespan, ether lipid biosynthesis is needed for specific longevity pathways, and that ether lipids might play a role in a shift to pro-longevity metabolism.
There are some points that require clarification and could benefit from additional study, some wording and presentation issues, and a few missing points of potential discussion.
Overall, the data reported in this paper contribute a highly valuable advance in the biguanide field and adds stimulating hypotheses to the scientific community for moving forward in this biomedically important area.
We thank Reviewer #1 for their positive feedback regarding our work, and for their insightful suggestions to improve the rigor and impact of this manuscript.
Reviewer #2 (Public Review):
This manuscript pulls together a series of integrated genetic and metabolomic data sets to examine the molecular basis for biguanide action in C. elegans. Biguanides such as Metformin are important anti-diabetic drugs as well as being explored as a therapeutic mechanism for increasing human longevity. Understanding the molecular basis of biguanide action is of general interest to those in the ageing and age-related health fields as well as to those studying metabolism and obesity. The work here has been carried out in C. elegans but the work can be picked up by those working in mammalian systems. More could be done to highlight the conserved aspects of the mechanisms involved to assist with this translatability.
The methodology used is in general standard in the field and experiments are reported in detail. The successful use of metabolomics in C. elegans and its associated protocols is helpful as more labs expand to do this type of work.
Strengths: In general all the experiments presented are logical and well executed with the conclusions supported by the data. I am convinced that: 1) Metformin and Phenformin extend C. elegans lifespan (although that has previously been shown), 2) biguanides induce changes in ether lipids, 3) genes required for ether lipid biogenesis are required for the lifespan incurred with biguanide treatment and, in the case of fard-1 oe, can also promote longevity when levels are increased, 4) ether lipid biogenesis is also needed for other specific key longevity processes to extend lifespan, and 5) that some key ageing regulators (skn-1, aak-2 and daf-16) are required for fard-1 oe to extend lifespan.
Weaknesses: I was less convinced by the fat accumulation data and felt that the link between skn-1 gain of function and ether lipid genes was not clear and that the results were more correlative than mechanistic. If age-associated somatic depletion of fat is important for the lifespans seen here then this is interesting and important and identifying an epistatic, genetic link between the implicated genes and fat levels is desirable. Additionally, biguanides are reported to have major effects on the metabolism and growth of bacteria. As C. elegans grows on and eats E. coli, it is important that the biguanides in question do not alter the worm's food source. If bacterial growth is restricted or metabolically altered this would have a major impact on fat metabolism and the other outputs examined here (see Cabreiro et al 2013). Therefore the impact of these biguanide treatments on the C. elegans foods used here should be clearly addressed. Additionally, biguanide treatment is subject to dose dependence. Different concentrations of biguanide are used for different types of experiments to make correlative points e.g. growth inhibition at 160mM metformin, and metformin uptake measured in C. elegans treated with 50mM. It is not clear why, or whether this could impact the results. Can the authors be sure that these different doses do not alter metformin action and/or uptake either by the worms or the way the bacteria metabolise it? I appreciate that it is interesting and important to understand what biguanides are doing in the organism irrespective of whether this is a direct or indirect effect but knowing how the effects are achieved could be important for treatment strategies moving forwards.
We thank Reviewer #2 for their favorable comments on our manuscript and for their helpful feedback regarding the weaknesses in our initial manuscript submission. We address the major comments below:
Regarding the genetic link between SKN-1 and ether lipid biosynthetic machinery in regulation of fat accumulation, we have performed Asdf analysis in skn-1(zu135) total loss-of-function animals, rigorously indicating that biguanides require SKN-1 to drive somatic lipid depletion (Figure 6D-E). We additionally show that biguanides activate the innate immune response sensor dod-24, previously shown by us to be activated by a transcriptionally redirected SKN-1 metabolic stress response program2, in a manner that requires both SKN-1 and all ether lipid biosynthetic machinery (Figure 6F and Figure 6 – figure supplement 1C). Combined with our previous result showing that fard-1 (oe3) requires SKN-1 to extend lifespan (Figure 5D), and our observation that SKN-1 gain-of-function animals do not mimic the ether lipid pattern seen in FARD-1 overexpressing animals (Reviewer Response 1), our results rigorously corroborate that biguanides activate SKN-1 downstream of ether lipid machinery to exert a metabolic stress defense response. This activation results in alterations of somatic lipid homeostasis, innate immune response, and pro-longevity outcomes.
Regarding possible indirect effects of biguanides on bacterial growth and metabolism to modulate ether lipid biosynthetic activity, we performed FAME GC/MS of Adult Day 1 nematodes treated with or without phenformin and grown on live or dead, metabolically inactive OP50-1 E. coli food sources using a rigorously established 1% PFA treatment protocol (Figure 6 – figure supplement 2)3. We additionally performed lifespan analyses in the same experimental design, with the inclusion of lifespan extending doses of metformin (Figure 6 – figure supplement 3). Both experiments show, with biological replication, that biguanide-mediated induction of ether lipid synthesis, biguanide-mediated lifespan extension, and the dependency of ether lipid machinery on biguanide-mediated lifespan extension all operate through direct interactions in the worm, as opposed to indirect effects on bacterial growth and metabolism.
Regarding the use of different doses of biguanides: this point was also raised by Reviewer 1 and is responded to above in Author Response 4. Briefly, the goal of the 160 mM dosage of metformin used in our prior genetic screens10 and subsequently highlighted in Figure 1 – figure supplement 1A is to enhance the sensitivity and specificity of our discovery approach to identify effectors of the biological action of biguanides. The 160 mM dose causes potent growth inhibition in C. elegans. Our prior published work indicates that use of this dose to identify growth inhibitory effectors of biguanides can also identify longevity effectors of metformin 10. Thus, we used a similar strategy here to identify fard-1 and acl-7, which were initially identified as gene knockdowns that block the growth inhibitory effects of 160 mM metformin. The justification for the different biguanide concentrations used in this work is now included in the text for clarity (lines 135 to 153).
-
eLife assessment
Using C. elegans as a model organism, the study hones in on the role of ether lipid biosynthesis as an effector of metformin--a process previously implicated in extending lifespan in response to diet--, TOR signalling, and mitochondrial interventions. The data in this paper are compelling, and a better understanding of biguanide impact on metabolism is highly important in the field.
-
Reviewer #1 (Public Review):
Cedillo et al. address the critically important question of how biguanides exert their positive effects on longevity using the powerful C. elegans model. Biguanides metformin and phenformin have been widely prescribed in the clinic to address metabolic challenges of diabetes; more recently the value of metformin in addressing specific cancers has emerged, and testing for impact on healthy human aging is getting underway. The need to understand the mechanism of biguanide action and the metabolic consequences of biguanide administration is clear.
The authors report that three genes that suppress longevity associated with metformin or phenformin treatment affect a common pathway for ether lipid biosynthesis; this ether lipid biosynthesis pathway is required for mitochondrial lifespan extension, eat-2 mediated …
Reviewer #1 (Public Review):
Cedillo et al. address the critically important question of how biguanides exert their positive effects on longevity using the powerful C. elegans model. Biguanides metformin and phenformin have been widely prescribed in the clinic to address metabolic challenges of diabetes; more recently the value of metformin in addressing specific cancers has emerged, and testing for impact on healthy human aging is getting underway. The need to understand the mechanism of biguanide action and the metabolic consequences of biguanide administration is clear.
The authors report that three genes that suppress longevity associated with metformin or phenformin treatment affect a common pathway for ether lipid biosynthesis; this ether lipid biosynthesis pathway is required for mitochondrial lifespan extension, eat-2 mediated dietary restriction longevity, and TOR inhibition-associated longevity, but not insulin pathway mediated longevity. Authors document with lipid profiling how ether lipids and some other lipids are impacted by phenformin vs. genetic disruption of ether lipid biosynthesis, define the tissue primarily responsible for the ether lipid biosynthesis, show that over-expression of enzyme fard-1 is sufficient to confer most of the phenformin effect, and implicate conserved stress transcription factor SKN-1 as a downstream outcome of the ether lipid change.
Strengths include the exploitation of the nematode model to address requirements not readily discerned in other models, the rigor of genetic documentation, the inclusion of metabolic profiling, the testing of multiple potential pathways that have been in the general discourse regarding metformin action, and the elaboration of a reasonably supported model that ether lipid biosynthesis is required for phenformin to activate longevity-promoting metabolic defenses downstream of conserved stress-responsive transcription factor SKN-1/NRF2. The novelty includes that ether lipids are directly linked to lifespan, ether lipid biosynthesis is needed for specific longevity pathways, and that ether lipids might play a role in a shift to pro-longevity metabolism.
There are some points that require clarification and could benefit from additional study, some wording and presentation issues, and a few missing points of potential discussion.
Overall, the data reported in this paper contribute a highly valuable advance in the biguanide field and adds stimulating hypotheses to the scientific community for moving forward in this biomedically important area.
-
Reviewer #2 (Public Review):
This manuscript pulls together a series of integrated genetic and metabolomic data sets to examine the molecular basis for biguanide action in C. elegans. Biguanides such as Metformin are important anti-diabetic drugs as well as being explored as a therapeutic mechanism for increasing human longevity. Understanding the molecular basis of biguanide action is of general interest to those in the ageing and age-related health fields as well as to those studying metabolism and obesity. The work here has been carried out in C. elegans but the work can be picked up by those working in mammalian systems. More could be done to highlight the conserved aspects of the mechanisms involved to assist with this translatability.
The methodology used is in general standard in the field and experiments are reported in detail. …
Reviewer #2 (Public Review):
This manuscript pulls together a series of integrated genetic and metabolomic data sets to examine the molecular basis for biguanide action in C. elegans. Biguanides such as Metformin are important anti-diabetic drugs as well as being explored as a therapeutic mechanism for increasing human longevity. Understanding the molecular basis of biguanide action is of general interest to those in the ageing and age-related health fields as well as to those studying metabolism and obesity. The work here has been carried out in C. elegans but the work can be picked up by those working in mammalian systems. More could be done to highlight the conserved aspects of the mechanisms involved to assist with this translatability.
The methodology used is in general standard in the field and experiments are reported in detail. The successful use of metabolomics in C. elegans and its associated protocols is helpful as more labs expand to do this type of work.
Strengths: In general all the experiments presented are logical and well executed with the conclusions supported by the data. I am convinced that: 1) Metformin and Phenformin extend C. elegans lifespan (although that has previously been shown), 2) biguanides induce changes in ether lipids, 3) genes required for ether lipid biogenesis are required for the lifespan incurred with biguanide treatment and, in the case of fard-1 oe, can also promote longevity when levels are increased, 4) ether lipid biogenesis is also needed for other specific key longevity processes to extend lifespan, and 5) that some key ageing regulators (skn-1, aak-2 and daf-16) are required for fard-1 oe to extend lifespan.
Weaknesses: I was less convinced by the fat accumulation data and felt that the link between skn-1 gain of function and ether lipid genes was not clear and that the results were more correlative than mechanistic. If age-associated somatic depletion of fat is important for the lifespans seen here then this is interesting and important and identifying an epistatic, genetic link between the implicated genes and fat levels is desirable. Additionally, biguanides are reported to have major effects on the metabolism and growth of bacteria. As C. elegans grows on and eats E. coli, it is important that the biguanides in question do not alter the worm's food source. If bacterial growth is restricted or metabolically altered this would have a major impact on fat metabolism and the other outputs examined here (see Cabreiro et al 2013). Therefore the impact of these biguanide treatments on the C. elegans foods used here should be clearly addressed. Additionally, biguanide treatment is subject to dose dependence. Different concentrations of biguanide are used for different types of experiments to make correlative points e.g. growth inhibition at 160mM metformin, and metformin uptake measured in C. elegans treated with 50mM. It is not clear why, or whether this could impact the results. Can the authors be sure that these different doses do not alter metformin action and/or uptake either by the worms or the way the bacteria metabolise it? I appreciate that it is interesting and important to understand what biguanides are doing in the organism irrespective of whether this is a direct or indirect effect but knowing how the effects are achieved could be important for treatment strategies moving forwards.
-
-
-